Journal
EPILEPSIA
Volume 58, Issue 2, Pages 181-221Publisher
WILEY
DOI: 10.1111/epi.13634
Keywords
Antiepileptic drugs; Drug development; Epilepsy; Epilepsy targets
Categories
Funding
- Alkaloid
- Arkin Holdings
- Boehringer Ingelheim
- Bial
- CTS Chemicals
- Teva
- Shire
- Upsher-Smith
- Vidac Pharma
- Israel Ministry of Defense
- Rafa Pharmaceuticals
- Biocodex
- European Union
- Italian Medicines Agency
- Italian Ministry of Health
- Italian Ministry for Education, University and Research
- Eisai
- Biopharm Solutions
- GW Pharma
- Mylan
- Sanofi
- Sun Pharma
- Takeda
- UCB Pharma
- Stockholm County Council
- CURE
- GlaxoSmithKline (GSK)
- UCB
- Novartis
- Department of Defense
- NIH/NINDS
Ask authors/readers for more resources
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26-29, 2016, and was attended by > 200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I-III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-D-glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE-217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec-butylpropylacetamide, FV-082, 1OP-2198, NAX 810-2, and SAGE-689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available